ACTRN12621000935831招募中未知
A pilot study to evaluate the diagnostic and therapeutic applications of FAPI-PET in pancreatic cancer.
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 62
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Diagnosis
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •This will be a dual centre, prospective, single arm study. We aim to recruit up to 12 patients in this initial phase of the study.
- •Key Inclusion criteria.
- •Patients referred to any hepato-pancreato-biliary (HPB) surgeon or oncologist with admitting rights at the Royal Brisbane and Women’s Hospital (RBWH) and Princess Alexandra Hospital (PAH) will be considered for inclusion. Patients will be recruited into 1 of 3 groups based on the following inclusion criteria:
- •a.Patients with pancreatic cancer and metastases. Must satisfy the following:
- •i.Histology / cytology specimen from primary or metastatic lesion highly suggestive of pancreatic or peri-ampullary adenocarcinoma.
- •ii.Distant metastases diagnosed on conventional cross-sectional imaging.
- •b.Patients with probable pancreatic cancer that is potentially resectable. Must satisfy the following:
- •i.Solid or infiltrating mass arising from pancreatic parenchyma on cross sectional imaging or common bile duct brushings highly suggestive of pancreatic or peri-ampullary adenocarcinoma.
- •ii.Has undergone cross sectional imaging of chest abdomen and pelvis without the diagnosis of metastases or local un-resectable features.
- •iii.Has not undergone direct biopsy of the tumour mass prior to FAPI-PET/CT.
- •c.c.Patients with a cystic pancreatic lesion without confirmed malignancy. Must satisfy the following:
- •i.Cystic pancreatic lesion detected on cross sectional imaging or endoscopic ultrasound.
- •ii.Patient exhibits at least one worrisome feature” or high-risk stigmata” according to Fukuoka guidelines: [Tanaka et al 2017: see below reference].
- •Additional Inclusion criteria.
- •i.No known problems of peripheral intravenous access.
- •ii.Able to provide informed, signed consent.
- •iii.All women of childbearing age considered for the study must have a pregnancy test prior to enrolment.
- •Tanaka, M., et al., Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology, 2017. 17(5): p. 738-753.
排除标准
- •Exclusion criteria
- •i.Aged under 18 years of age.
- •ii.Administered a radioisotope within 5 half-lives prior to the intended scan.
- •iii.Patients with allergies to the FAPI or FDG PET tracer.
- •iv.Pregnant patients.
- •v.Patients who have started chemotherapy or radiotherapy for their disease prior to FAPI-PET/CT.
- •vi.Patients who have undergone surgery for their disease prior to FAPI-PET/CT.
- •vii.Unable to lie flat to tolerate PET scanning.
- •viii.Prior history of other malignancy within the last 2 years.
研究者
相似试验
尚未招募
2 期
A Pilot Clinical study of Siddha Medicine in the treatment of Pen Maladu (Female Infertility)CTRI/2017/03/008067ational Institute of Siddha10
尚未招募
2 期
A Study to find the Effectiveness of Siddha treatment for Vathakarsanam (Diabetic Peripheral Neuropathy)CTRI/2024/06/069492I
尚未招募
3 期
Evaluation of the Effect of deferasirox on the treatment of ??Acute myeloid leukemiaAcute myeloblastic leukemiaIRCT20200313046756N2Kerman University of Medical Sciences40
已完成
不适用
The impact of therapeutic Human Immunodeficiency Virus (HIV) vaccination followed by antiretroviral therapy in patients with prolonged viral suppressioHuman Immunodeficiency Virus (HIV)Infections and InfestationsHuman immunodeficiency virus (HIV)ISRCTN87061665Ottawa Hospital Research Institute (Canada)60
已完成
不适用
To evaluate clinical efficacy and safety of autologous serum injection therapyDiseases of the skin and subcutaneous tissueKCT0001971Ajou University Hospital50